What diseases are associated with positive anti‑SSA (Ro) and anti‑SSB (La) antibodies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What Causes Positive SSA and SSB Antibodies

Positive anti-SSA (Ro) and anti-SSB (La) antibodies are most strongly associated with Sjögren's syndrome and systemic lupus erythematosus (SLE), with Sjögren's syndrome being the primary disease where these antibodies serve as diagnostic hallmarks.

Primary Disease Associations

Sjögren's Syndrome

  • Anti-SSA/Ro and anti-La/SSB are the hallmark antibodies in primary Sjögren's syndrome, present in 60-70% of patients 1
  • These antibodies are included in the classification criteria for Sjögren's syndrome and help identify more "active" patients with systemic involvement 1
  • Patients positive for these antibodies demonstrate earlier disease onset, more severe glandular dysfunction, and increased extraglandular manifestations 1
  • The presence of anti-Ro/La predicts systemic, extraglandular disease rather than isolated exocrine gland involvement 2

Systemic Lupus Erythematosus

  • Anti-Ro/SSA antibodies occur in approximately 10% of diagnosed SLE patients, while anti-La/SSB appears in 22% 3
  • In SLE patients positive for these antibodies, the most prominent features include skin involvement and sicca complex in 60% of cases 3
  • These antibodies are associated with renal involvement (66%), joint complaints (56%), and skin or malar rash (46%) in SLE patients 3

Secondary Disease Associations

Rheumatoid Arthritis with Overlap Features

  • Anti-Ro/SSA positivity occurs in 17.4% of rheumatoid arthritis patients, while anti-La/SSB appears in 39.1% 3
  • When present in RA patients, anti-SSB/La and anti-SSA/Ro typically indicate concurrent Sjögren's syndrome 4
  • Anti-180kD antibodies in RA patients are specifically associated with lymphadenopathy and Sjögren's syndrome 4

Other Connective Tissue Diseases

  • These antibodies are sometimes detected in other systemic autoimmune diseases beyond SLE and Sjögren's syndrome 5
  • The clinical importance of anti-Ro/SSA antibodies has expanded across various autoimmune conditions in recent decades 5

Predictive and Prognostic Significance

Future Disease Development

  • Anti-Ro and anti-La found among healthy individuals, including mothers of infants with neonatal lupus, predict future development of connective tissue disease 2
  • The presence of these antibodies precedes clinical manifestations and serves as an early marker for autoimmune disease risk 2

Immunogenetic Background

  • Autoantibody formation has a stronger association with HLA-DR2 and HLA-DR3 genetic markers 1
  • The immunogenetic background plays an important role in determining which individuals develop these antibodies 1

Clinical Implications for Evaluation

When encountering positive SSA/SSB antibodies, evaluate for:

  • Sicca symptoms (dry eyes, dry mouth) suggesting Sjögren's syndrome 1
  • Systemic manifestations including skin rashes, joint pain, renal involvement, and lymphadenopathy 3, 1
  • Glandular dysfunction through objective testing (Schirmer's test, salivary flow) 1
  • Other B cell activation markers and serologic features that cluster with these antibodies 1

Special Consideration in Pregnancy

  • Women with anti-Ro/SSA and/or anti-La/SSB antibodies face a 2% risk of complete heart block in first pregnancies and 13-18% in subsequent pregnancies after an affected infant 6, 7
  • Serial fetal echocardiography starting at 16-18 weeks through week 26 is recommended 6, 7

References

Research

Prognostic value of Sjögren's syndrome autoantibodies.

Journal of laboratory and precision medicine, 2018

Research

Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders.

The Journal of the Association of Physicians of India, 2002

Research

Clinical and pathological roles of Ro/SSA autoantibody system.

Clinical & developmental immunology, 2012

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fetal Echocardiogram Timing in SSA-Positive Pregnancies

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the significance of anti-SSA (Sjögren's syndrome antigen A)/Ro antibodies?
What is the likely diagnosis and treatment plan for a patient with elevated Anti-SSA and Anti-SSB antibodies, impaired renal function, and elevated ESR?
What is the role of autoantibodies, such as anti-SSA (Ro) and anti-SSB (La), in the diagnosis and management of Sjögren's syndrome?
What is the initial approach for an autoimmune screen in a patient like Anatoly?
What is the management approach for elevated anti-RO antibodies?
In an adult patient with a hypertensive emergency (systolic ≥180 mm Hg or diastolic ≥120 mm Hg) and no specific organ involvement, what are the target blood pressure goals and the recommended initial intravenous antihypertensive agents with their dosing and titration?
What are the normal fetal biometry values (biparietal diameter, head circumference, abdominal circumference, femur length, estimated fetal weight) and uterine fundal height at 29 weeks gestation in a normally growing singleton?
In a 28-year-old woman with a painful 2 × 3 cm fluctuating breast lump that is anechoic on ultrasound with a hypervascular wall and no septations, what is the most appropriate management?
How does amlodipine affect migraine?
In a patient with chronic kidney disease who has normal‑sized kidneys on ultrasound, how should I evaluate the underlying cause and manage the condition?
For a patient with type 1 or type 2 diabetes requiring basal insulin, should I use insulin degludec (Tresiba) or insulin glargine (Lantus/Toujeo) considering hypoglycemia risk, renal function, dosing flexibility, and cost?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.